tiprankstipranks
Trending News
More News >
BaTeLab Co., Ltd. (HK:2149)
:2149
Hong Kong Market
Advertisement

BaTeLab Co., Ltd. (2149) AI Stock Analysis

Compare
2 Followers

Top Page

HK:2149

BaTeLab Co., Ltd.

(2149)

Rating:72Outperform
Price Target:
HK$65.00
▲(26.21% Upside)
BaTeLab Co., Ltd. scores well due to strong financial performance, particularly in revenue growth and profitability. Technical analysis suggests mixed signals with short-term weakness but longer-term strength. Valuation is fair, though the lack of a dividend yield is a downside for income investors. Cash flow management remains a key area for improvement.
Positive Factors
Financial Performance
The company's FY24 revenue went up by 25% YoY to RMB579mn, and NP surged by 52% YoY to RMB167mn.
Growth Prospects
BaTeLab remains one of the top convictions in the semiconductor universe, with optimism on its long-term growth prospect as it continues to build up its product portfolio and a robust IP/EDA design platform supporting the long-tail industrial market.
Negative Factors
Capacity Constraints
Capacity constraints may cap near-term growth, as tight foundry capacity might limit revenue upside despite signs of recovery in the industrial analog market.
Gross Profit Margin
GPM declined 2.4ppt to 53% in FY24 mainly due to the impact of provisions for inventory impairment.

BaTeLab Co., Ltd. (2149) vs. iShares MSCI Hong Kong ETF (EWH)

BaTeLab Co., Ltd. Business Overview & Revenue Model

Company DescriptionBaTeLab Co., Ltd. (2149) is a leading company specializing in biotechnology and life sciences, focused on developing innovative solutions and products that enhance healthcare and improve quality of life. The company operates in sectors such as pharmaceuticals, medical devices, and diagnostics, providing a range of core products including advanced therapeutics, diagnostic tools, and health management solutions.
How the Company Makes MoneyBaTeLab Co., Ltd. generates revenue through multiple channels, primarily by selling its proprietary pharmaceutical products and medical devices to healthcare institutions and directly to consumers. The company also earns income from licensing its technologies and patents to other firms in the biotechnology sector. Additionally, BaTeLab has established strategic partnerships with major healthcare providers and research institutions, which enhance its market reach and credibility. Grants and funding from governmental and non-governmental organizations for research and development projects further contribute to its earnings, allowing the company to innovate and expand its product portfolio.

BaTeLab Co., Ltd. Financial Statement Overview

Summary
BaTeLab Co., Ltd. shows strong revenue growth and profitability with a solid balance sheet. However, cash flow management needs improvement, particularly in generating positive free cash flow.
Income Statement
85
Very Positive
BaTeLab Co., Ltd. has demonstrated strong revenue growth with a significant increase from the previous year, indicating robust market demand. The gross profit margin is healthy, and the net profit margin has improved, reflecting efficient cost management. The EBIT and EBITDA margins are also solid, showcasing operational efficiency. Overall, the income statement reflects a positive growth trajectory and profitability.
Balance Sheet
78
Positive
The balance sheet of BaTeLab Co., Ltd. shows a strong equity position with a favorable equity ratio, indicating financial stability. The debt-to-equity ratio is moderate, suggesting manageable leverage levels. Return on equity is impressive, highlighting effective utilization of equity capital. However, the increase in total debt warrants monitoring to ensure it remains within sustainable levels.
Cash Flow
70
Positive
BaTeLab Co., Ltd. has experienced challenges in generating positive free cash flow, which is a concern despite positive operating cash flow. The free cash flow to net income ratio is negative, indicating potential issues in converting earnings into cash. However, the operating cash flow to net income ratio is positive, suggesting that operational activities are generating cash, albeit not enough to cover capital expenditures.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue578.81M463.88M409.93M256.36M99.69M
Gross Profit306.92M257.11M231.79M144.63M54.78M
EBITDA144.94M119.02M101.89M63.53M19.35M
Net Income166.60M109.16M95.26M56.97M13.99M
Balance Sheet
Total Assets1.61B1.27B668.62M435.55M203.52M
Cash, Cash Equivalents and Short-Term Investments636.02M550.84M206.20M179.55M80.02M
Total Debt325.22M182.63M189.97M45.13M24.06M
Total Liabilities603.81M432.70M224.20M67.87M163.43M
Stockholders Equity1.01B838.23M444.42M367.68M40.08M
Cash Flow
Free Cash Flow-20.34M-13.40M-34.68M-33.62M-54.21M
Operating Cash Flow13.56M30.28M-12.91M10.03M-47.71M
Investing Cash Flow-63.95M-41.70M-18.58M53.80M-5.21M
Financing Cash Flow127.56M400.68M49.78M96.88M53.69M

BaTeLab Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price51.50
Price Trends
50DMA
58.51
Negative
100DMA
56.67
Negative
200DMA
43.97
Positive
Market Momentum
MACD
-1.43
Positive
RSI
39.87
Neutral
STOCH
16.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2149, the sentiment is Negative. The current price of 51.5 is below the 20-day moving average (MA) of 58.50, below the 50-day MA of 58.51, and above the 200-day MA of 43.97, indicating a neutral trend. The MACD of -1.43 indicates Positive momentum. The RSI at 39.87 is Neutral, neither overbought nor oversold. The STOCH value of 16.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2149.

BaTeLab Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (56)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
HK$3.38B16.9116.76%5.19%34.68%
56
Neutral
$6.44B4.44-14.04%6.05%10.91%8.39%
$5.31B32.917.18%
€127.99M16.674.98%
65
Neutral
HK$3.27B7.8517.96%5.59%-18.35%-6.00%
51
Neutral
HK$93.18B213.321.36%0.35%7.67%-9.17%
45
Neutral
HK$92.42M68.18-41.46%-26.02%-4977.27%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2149
BaTeLab Co., Ltd.
53.55
26.10
95.08%
SFDMF
Shanghai Fudan Microelectronics Group Co
2.32
1.10
90.16%
DE:RZF
Solomon Systech (International) Ltd.
0.04
0.02
100.00%
HK:1347
Hua Hong Semiconductor Ltd.
47.02
31.76
208.13%
HK:8490
Niche-Tech Semiconductor Materials Limited
0.12
-0.05
-29.41%
HK:0085
China Electronics Huada Technology Company Limited
1.55
0.62
66.67%

BaTeLab Co., Ltd. Corporate Events

BaTeLab Co., Ltd. Schedules Board Meeting for Interim Results
Aug 12, 2025

BaTeLab Co., Ltd. has announced that its board of directors will hold a meeting on August 22, 2025, to consider and approve the interim results for the first half of the year ending June 30, 2025. This meeting is significant as it will determine the company’s financial performance for the period and could impact its market positioning and stakeholder interests.

BaTeLab Co., Ltd. Announces Key Leadership Changes
Jul 3, 2025

BaTeLab Co., Ltd. announced significant changes in its corporate governance structure, including the resignation of Mr. Cheung Kai Cheong Willie as joint company secretary and the appointment of Mr. Chung Ming Fai in his place, effective July 3, 2025. Additionally, Mr. Zhang Guangping has been elected as the chairman of the board and authorized representative, reflecting a strategic move to strengthen the company’s leadership and compliance framework.

BaTeLab Co., Ltd. Announces Board Composition and Roles
Jun 27, 2025

BaTeLab Co., Ltd., a joint stock company incorporated in the People’s Republic of China, has announced the composition of its board of directors and their respective roles within the company’s committees. The announcement details the executive, non-executive, and independent non-executive directors, highlighting the leadership roles within the audit, remuneration and evaluation, nomination, and strategy committees. This organizational update may impact the company’s governance and strategic direction, potentially influencing stakeholder confidence and market perception.

BaTeLab Co., Ltd. Forms Nomination Committee to Strengthen Governance
Jun 27, 2025

BaTeLab Co., Ltd. has announced the establishment of a Nomination Committee by its board of directors. This committee will consist of at least three members, with a majority being independent non-executive directors, and will include at least one director of a different gender. The committee’s formation is a strategic move to enhance corporate governance, ensuring diverse and independent oversight in the company’s nomination processes, which could positively impact stakeholder confidence and the company’s industry positioning.

BaTeLab Co., Ltd. Successfully Concludes AGM with Unanimous Approval of Resolutions
Jun 27, 2025

BaTeLab Co., Ltd., a company based in the People’s Republic of China, successfully held its Annual General Meeting (AGM) on June 27, 2025, where all proposed resolutions were approved by the shareholders. The meeting, attended by shareholders holding approximately 66.54% of the total issued shares, resulted in unanimous approval of key resolutions including the 2024 annual report, audited financial statements, and the appointment of auditors for 2025. The AGM was conducted in compliance with the relevant legal and regulatory requirements, with no shareholders abstaining or voting against the resolutions.

BaTeLab Co., Ltd. Announces 2024 AGM with Key Resolutions
Jun 6, 2025

BaTeLab Co., Ltd. has announced its 2024 Annual General Meeting (AGM) to be held on June 27, 2025, in Nantong, Jiangsu Province, China. The AGM will address several key resolutions, including the approval of the 2024 annual report, audited financial statements, and profit distribution plan. Additionally, the meeting will involve the election of directors for the second session of the Board, amendments to corporate governance systems, and the abolishment of the Supervisory Committee. These decisions are crucial for the company’s governance and strategic direction, potentially impacting its market positioning and stakeholder relations.

BaTeLab Co., Ltd. Announces Changes in Auditor and Board Structure
Jun 6, 2025

BaTeLab Co., Ltd. has announced several significant changes to its corporate governance structure, including the proposed change of its auditor, the election of new directors for the second session of the board, and the abolishment of its supervisory committee. The company plans to replace KPMG with Rongcheng (Hong Kong) CPA Limited as its auditor to enhance cost-effectiveness and maintain independence in its audit services. Additionally, the company has nominated a new set of directors for the upcoming session, with the term set to last three years, pending approval at the annual general meeting.

BaTeLab Co., Ltd. Approves Strategic Changes at 2025 EGM
Jun 3, 2025

BaTeLab Co., Ltd. successfully held its first extraordinary general meeting of 2025 on June 3, where shareholders approved a special resolution to change the company’s name and domicile, along with amendments to its Articles of Association. This decision marks a significant step in the company’s strategic plans, potentially impacting its market positioning and operational framework once all necessary regulatory approvals are obtained.

BaTeLab Co., Ltd. Completes H Shares Placement to Boost Manufacturing
May 28, 2025

BaTeLab Co., Ltd. announced the completion of placing 3,000,000 H Shares, raising approximately HK$116.58 million. The proceeds will be used to invest in upstream manufacturing resources and general working capital, which will enhance the company’s competitiveness by ensuring stable production capacity and innovation in manufacturing processes.

BaTeLab Co., Ltd. Announces New H Share Placement to Raise HK$116.58 Million
May 21, 2025

BaTeLab Co., Ltd. has announced a placement of new H shares under a general mandate, aiming to raise approximately HK$116.58 million in net proceeds. The placement involves up to 3,000,000 shares at HK$40.00 each, representing a significant portion of the company’s existing and enlarged share capital. The funds are expected to enhance the company’s financial position, though the placement is conditional and may not proceed if certain conditions are not met.

BaTeLab Co., Ltd. Announces Proposed Name and Domicile Change
May 15, 2025

BaTeLab Co., Ltd., a joint stock limited company incorporated in China, has announced a proposed change of its company name and domicile. The company plans to relocate its domicile from Suzhou to Nanjing and change its Chinese name, pending approval from relevant authorities. This change is intended to align with the company’s business development needs. The proposed changes will not affect shareholders’ rights, and existing share certificates will remain valid. The changes are subject to shareholder approval and necessary regulatory filings.

BaTeLab Co., Ltd. Announces 2025 Extraordinary General Meeting
May 15, 2025

BaTeLab Co., Ltd. has announced that it will hold its first extraordinary general meeting (EGM) of 2025 on June 3rd to consider a special resolution regarding the change of the company’s name and domicile, along with amendments to its Articles of Association. This meeting is significant as it could impact the company’s operational structure and governance, potentially influencing its market positioning and stakeholder relations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 27, 2025